Moleculin Biotech (MBRX) just unveiled an announcement.
Moleculin Biotech, Inc. has successfully concluded its End of Phase 2 meeting with the FDA regarding its Annamycin and Cytarabine combination treatment for acute myeloid leukemia (AML). This treatment is aimed at new patients and those who haven’t responded to initial therapy. The outcomes of the meeting will be shared after the official minutes are received by the end of the third quarter of 2024. This advancement marks a significant milestone for the company’s innovative approach to combating AML.
Learn more about MBRX stock on TipRanks’ Stock Analysis page.
